115 related articles for article (PubMed ID: 9213355)
1. Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors.
Azizeh BY; Van Tine BA; Trivedi D; Hruby VJ
Peptides; 1997; 18(5):633-41. PubMed ID: 9213355
[TBL] [Abstract][Full Text] [Related]
2. Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists.
Van Tine BA; Azizeh BY; Trivedi D; Phelps JR; Houslay MD; Johnson DG; Hruby VJ
Endocrinology; 1996 Aug; 137(8):3316-22. PubMed ID: 8754757
[TBL] [Abstract][Full Text] [Related]
3. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
[TBL] [Abstract][Full Text] [Related]
4. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
[TBL] [Abstract][Full Text] [Related]
5. Synthetic glucagon antagonists and partial agonists.
Zechel C; Trivedi D; Hruby VJ
Int J Pept Protein Res; 1991 Aug; 38(2):131-8. PubMed ID: 1664420
[TBL] [Abstract][Full Text] [Related]
6. Synthetic linear and cyclic glucagon antagonists.
Dharanipragada R; Trivedi D; Bannister A; Siegel M; Tourwe D; Mollova N; Schram K; Hruby VJ
Int J Pept Protein Res; 1993 Jul; 42(1):68-77. PubMed ID: 8396562
[TBL] [Abstract][Full Text] [Related]
7. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist.
Unson CG; Gurzenda EM; Merrifield RB
Peptides; 1989; 10(6):1171-7. PubMed ID: 2560175
[TBL] [Abstract][Full Text] [Related]
8. Synthetic peptide antagonists of glucagon.
Unson CG; Andreu D; Gurzenda EM; Merrifield RB
Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
[TBL] [Abstract][Full Text] [Related]
9. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
[TBL] [Abstract][Full Text] [Related]
10. Glucagon: structure-function relationships investigated by sequence deletions.
Frandsen EK; Grønvald FC; Heding LG; Johansen NL; Lundt BF; Moody AJ; Markussen J; Vølund A
Hoppe Seylers Z Physiol Chem; 1981 Jun; 362(6):665-77. PubMed ID: 6268519
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system.
Post SR; Rubinstein PG; Tager HS
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1662-6. PubMed ID: 8383321
[TBL] [Abstract][Full Text] [Related]
12. Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding.
Unson CG; Macdonald D; Ray K; Durrah TL; Merrifield RB
J Biol Chem; 1991 Feb; 266(5):2763-6. PubMed ID: 1847133
[TBL] [Abstract][Full Text] [Related]
13. Activation of the hepatic glycine cleavage enzyme system by glucagon and glucagon-related peptides.
Mabrouk GM; Brosnan JT
Can J Physiol Pharmacol; 1997 Sep; 75(9):1096-100. PubMed ID: 9365819
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the presynaptic A2a-adenosine receptor of the rat motor nerve endings is positively coupled to adenylate cyclase.
Correia-de-Sá P; Ribeiro JA
Naunyn Schmiedebergs Arch Pharmacol; 1994 Nov; 350(5):514-22. PubMed ID: 7870191
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram.
Yamashita N; Yamauchi M; Baba J; Sawa A
Eur J Pharmacol; 1997 Oct; 337(1):95-102. PubMed ID: 9389386
[TBL] [Abstract][Full Text] [Related]
16. Effects of intracerebroventricular injections of des-His1 (Glu9) glucagon amide on the regulatory thermogenesis in muscovy ducklings.
Abdelmelek H; Fechtali T; Rouanet JL; Montaron A; Lachuer J; Pequignot JM; Barré H
C R Acad Sci III; 2000 Mar; 323(3):267-71. PubMed ID: 10782330
[TBL] [Abstract][Full Text] [Related]
17. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Gordeladze JO
Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
[TBL] [Abstract][Full Text] [Related]
18. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
[TBL] [Abstract][Full Text] [Related]
19. Identification of an essential serine residue in glucagon: implication for an active site triad.
Unson CG; Merrifield RB
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):454-8. PubMed ID: 8290548
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat.
Robberecht P; Waelbroeck M; Camus JC; De Neef P; Coy DH; Christophe J
Peptides; 1986; 7 Suppl 1():109-12. PubMed ID: 3018688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
